 DURHAM, N.C. and AUSTIN, Texas, Oct. 29, 2020 GLOBE NEWSWIRE -- Shattuck Labs, Inc. Shattuck NASDAQ: STTK, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the CD47SIRPα Summit 2020 being held virtually November 4-5, 2020. 